Article Information
History
- March 24, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Prof Conghua Xie, PhD1,2,3,*,†,
- Xiaoyong Wang, MS1,2,3,*,
- Hui Liu, MS1,2,3,*,
- Zhirong Bao, MS1,2,3,
- Jing Yu, PhD1,2,3,
- Yahua Zhong, PhD1,2,3 and
- Melvin L.K. Chua, PhD1,4,5,†
- 1Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
- 2Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
- 3Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
- 4Division of Radiation Oncology, Division of Medical Sciences, National Cancer Centre Singapore, Singapore
- 5Oncology Academic Programme, Duke-NUS Medical School, Singapore
- ↵†Correspondence to: Prof Conghua Xie, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, People’s Republic of China. E-mail: chxie_65{at}whu.edu.cn; Tel: +86-27-67812607; Fax: +86-27-67812889, Dr Melvin L.K. Chua, Division of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610. E-mail: melvin.chua.l.k{at}singhealth.com.sg; Tel: +65-64368000.
↵* Co-first authors who contributed equally to the work
Posted March 24, 2020.
Infection Control of 2019 Novel Corona Virus Disease (COVID-19) in Cancer Patients undergoing Radiotherapy in Wuhan
